Paragraph IV Gets A Date: FDA Will Announce When ANDAs Are Submitted
FDA will begin posting the date when Paragraph IV applications are filed, FDA Commissioner McClellan told the Generic Pharmaceutical Association annual meeting March 2 in Boca Raton, Fla
You may also be interested in...
FDA will re-examine whether it is legally barred from notifying a generic company early in the ANDA process that it is the first filer eligible for 180-day exclusivity, Chief Counsel Dan Troy said Sept. 30
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials